Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 20, 2003. The report details specific corporate actions regarding share re-purchases and updates on directors' interests in company shares, rather than presenting comprehensive financial results for a fiscal quarter or year.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to a specific share transaction:
- Share Re-purchase Price: 1,272.01 pence per share.
- ADR Average Price (Retirement Plan): $41.70.
Material Changes
The filing reports the following material changes and transactions:
- Share Cancellation: On June 19, 2003, the company purchased 1,175,000 Ordinary 25 pence shares for cancellation, utilizing authority granted at the Annual General Meeting on May 19, 2003.
- Retirement Plan Holdings: The GlaxoSmithKline US Retirement Savings Plan saw a decrease in Ordinary Share ADRs from 18,702,194 to 18,667,673 due to fund movements on June 19, 2003.
- Employee Trust Transfer: On June 18, 2003, the GSK Trust transferred 28,038 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. It is strictly a notification of regulatory compliance regarding share transactions and director interests.
Key Facts for Investor Verification
- Verify the total number of shares repurchased for cancellation (1,175,000) and the total cost incurred.
- Confirm the impact of the share buyback on the company's total share count and earnings per share.
- Review the specific holdings of directors Dr. J-P Garnier and Mr. J D Coombe in relation to the GSK Trust and US Retirement Savings Plan.
- Check subsequent filings for the full financial impact of these transactions on the company's balance sheet.